Terms: = Kidney tumors AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12 AND Treatment
33 results:
1. Diagnosis and treatment of bilateral adrenal pheochromocytoma with ret gene mutation combined with medullary sponge kidney: A case report.
Shen P; Yin N; Sun L; Liu Y; Cao X
Medicine (Baltimore); 2023 Jun; 102(23):e34022. PubMed ID: 37335636
[TBL] [Abstract] [Full Text] [Related]
2. Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers.
Jin J; Xie Y; Zhang JS; Wang JQ; Dai SJ; He WF; Li SY; Ashby CR; Chen ZS; He Q
Drug Resist Updat; 2023 Mar; 67():100929. PubMed ID: 36739809
[TBL] [Abstract] [Full Text] [Related]
3. Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non-small cell lung cancer patients with impaired renal function: RESTART trial.
Shiraishi Y; Kishimoto J; Shimose T; Toi Y; Sugawara S; Okamoto I
BMC Cancer; 2022 Sep; 22(1):964. PubMed ID: 36076179
[TBL] [Abstract] [Full Text] [Related]
4. Novel Therapeutics for Advanced Differentiated Thyroid Cancer.
Lieberman L; Worden F
Endocrinol Metab Clin North Am; 2022 Jun; 51(2):367-378. PubMed ID: 35662446
[TBL] [Abstract] [Full Text] [Related]
5. Sorafenib in Metastatic Papillary Thyroid Carcinoma with
Caterino M; Pirozzi M; Facchini S; Zotta A; Sica A; Lo Giudice G; Rauso R; Varriale E; Ciardiello F; Fasano M
Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630083
[TBL] [Abstract] [Full Text] [Related]
6. Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the treatment of Cancer: A Review.
Unnisa A; Chettupalli AK; Hussain T; Kamal MA
Anticancer Agents Med Chem; 2022; 22(20):3370-3381. PubMed ID: 35400324
[TBL] [Abstract] [Full Text] [Related]
7. ret receptor signaling: Function in development, metabolic disease, and cancer.
Takahashi M
Proc Jpn Acad Ser B Phys Biol Sci; 2022; 98(3):112-125. PubMed ID: 35283407
[TBL] [Abstract] [Full Text] [Related]
8. Mesenchymal neoplasms with NTRK and other kinase gene alterations.
Davis JL; Al-Ibraheemi A; Rudzinski ER; Surrey LF
Histopathology; 2022 Jan; 80(1):4-18. PubMed ID: 34958503
[TBL] [Abstract] [Full Text] [Related]
9. OLFM4-ret fusion is an oncogenic driver in small intestine adenocarcinoma.
Liu W; Li H; Aerbajinai W; Botos I; Rodgers GP
Oncogene; 2022 Jan; 41(1):72-82. PubMed ID: 34675408
[TBL] [Abstract] [Full Text] [Related]
10. Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence.
Santoni M; Iacovelli R; Colonna V; Klinz S; Mauri G; Nuti M
Expert Rev Anticancer Ther; 2021 Sep; 21(9):1029-1054. PubMed ID: 34445927
[TBL] [Abstract] [Full Text] [Related]
11. A Novel Risk Stratification System for Thyroid Nodules With Indeterminate Cytology-A Pilot Cohort Study.
Gomes-Lima CJ; Auh S; Thakur S; Zemskova M; Cochran C; Merkel R; Filie AC; Raffeld M; Patel SB; Xi L; Wartofsky L; Burman KD; Klubo-Gwiezdzinska J
Front Endocrinol (Lausanne); 2020; 11():53. PubMed ID: 32132976
[No Abstract] [Full Text] [Related]
12. Updates on the Management of Thyroid Cancer.
Araque KA; Gubbi S; Klubo-Gwiezdzinska J
Horm Metab Res; 2020 Aug; 52(8):562-577. PubMed ID: 32040962
[TBL] [Abstract] [Full Text] [Related]
13. TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.
Baba M; Furuya M; Motoshima T; Lang M; Funasaki S; Ma W; Sun HW; Hasumi H; Huang Y; Kato I; Kadomatsu T; Satou Y; Morris N; Karim BO; Ileva L; Kalen JD; Wilan Krisna LA; Hasumi Y; Sugiyama A; Kurahashi R; Nishimoto K; Oyama M; Nagashima Y; Kuroda N; Araki K; Eto M; Yao M; Kamba T; Suda T; Oike Y; Schmidt LS; Linehan WM
Mol Cancer Res; 2019 Aug; 17(8):1613-1626. PubMed ID: 31043488
[TBL] [Abstract] [Full Text] [Related]
14. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer.
Cabanillas ME; Takahashi S
Semin Oncol; 2019 Feb; 46(1):57-64. PubMed ID: 30685073
[TBL] [Abstract] [Full Text] [Related]
15. Familial and Hereditary Forms of Primary Hyperparathyroidism.
Cetani F; Saponaro F; Borsari S; Marcocci C
Front Horm Res; 2019; 51():40-51. PubMed ID: 30641519
[TBL] [Abstract] [Full Text] [Related]
16. Lenvatinib for the treatment of renal cell carcinoma.
Roviello G; Corona SP; Bozza G; Aieta M; Generali D; Rodriquenz MG; Mileo AM; Imperatori M; Ianza A; Conca R; Sobhani N
Expert Opin Investig Drugs; 2018 May; 27(5):507-512. PubMed ID: 29718721
[TBL] [Abstract] [Full Text] [Related]
17. [Cabozantinib: Mechanism of action, efficacy and indications].
Cochin V; Gross-Goupil M; Ravaud A; Godbert Y; Le Moulec S
Bull Cancer; 2017 May; 104(5):393-401. PubMed ID: 28477875
[TBL] [Abstract] [Full Text] [Related]
18. Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer.
Ma X; Wang L; Li H; Zhang Y; Gao Y; Guo G; Liu K; Meng Q; Zhao C; Wang D; Song Z; Zhang X
Sci Rep; 2016 Aug; 6():30886. PubMed ID: 27488093
[TBL] [Abstract] [Full Text] [Related]
19. Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.
Glen H
Future Oncol; 2016 Oct; 12(19):2195-204. PubMed ID: 27339111
[TBL] [Abstract] [Full Text] [Related]
20. Central role of ret in thyroid cancer.
Santoro M; Carlomagno F
Cold Spring Harb Perspect Biol; 2013 Dec; 5(12):a009233. PubMed ID: 24296167
[TBL] [Abstract] [Full Text] [Related]
[Next]
